AstraZeneca PLC (AZN) Investors Who Lost Money Have Opportunity to Lead Securities Fraud Lawsuit

21.01.25 18:00 Uhr

Werte in diesem Artikel
Aktien

140,90 EUR 0,70 EUR 0,50%

LOS ANGELES, Jan. 21, 2025 /PRNewswire/ -- The Law Offices of Frank R. Cruz announces that investors with losses related to AstraZeneca PLC ("AstraZeneca" or the "Company") (NASDAQ: AZN) have opportunity to lead the securities fraud class action lawsuit.

(PRNewsfoto/The Law Offices of Frank R. Cru)

IF YOU ARE AN INVESTOR WHO SUFFERED A LOSS IN ASTRAZENECA PLC (AZN), CLICK HERE BEFORE FEBRUARY 21, 2025 (THE LEAD PLAINTIFF DEADLINE) TO PARTICIPATE IN THE ONGOING SECURITIES FRAUD LAWSUIT.

What Is The Lawsuit About?
The complaint filed alleges that, between February 23, 2022 and December 17, 2024, Defendants failed to disclose to investors that: (1) AstraZeneca engaged in insurance fraud in China; (2) as a result, AstraZeneca faced heightened legal exposure in China, which eventually resulted in the AstraZeneca China President being detained by Chinese law enforcement authorities; (3) as a result, AstraZeneca understated its legal risks; (4) the foregoing, once revealed, could materially harm AstraZeneca's business activities in China; and (5) as a result, Defendants' positive statements about the Company's business, operations, and prospects were materially misleading and/or lacked a reasonable basis at all relevant times.

Contact Us To Participate or Learn More:

If you wish to learn more about this action, or if you have any questions concerning this announcement or your rights or interests with respect to these matters, please contact us.
The Law Offices of Frank R. Cruz, 
Email us at: info@frankcruzlaw.com
Call us at: 310-914-5007
Visit our website at: www.frankcruzlaw.com
Follow us for updates on Twitter: twitter.com/FRC_LAW.

If you inquire by email, please include your mailing address, telephone number, and number of shares purchased.

To be a member of the class action you need not take any action at this time; you may retain counsel of your choice or take no action and remain an absent member of the class action.  

This press release may be considered Attorney Advertising in some jurisdictions under the applicable law and ethical rules.

Cision View original content to download multimedia:https://www.prnewswire.com/news-releases/astrazeneca-plc-azn-investors-who-lost-money-have-opportunity-to-lead-securities-fraud-lawsuit-302354915.html

SOURCE The Law Offices of Frank R. Cruz, Los Angeles

Ausgewählte Hebelprodukte auf AstraZeneca

Mit Knock-outs können spekulative Anleger überproportional an Kursbewegungen partizipieren. Wählen Sie einfach den gewünschten Hebel und wir zeigen Ihnen passende Open-End Produkte auf AstraZeneca

NameHebelKOEmittent
NameHebelKOEmittent
Wer­bung

Nachrichten zu AstraZeneca PLC

Wer­bung

Analysen zu AstraZeneca PLC

DatumRatingAnalyst
11:16AstraZeneca BuyGoldman Sachs Group Inc.
07.02.2025AstraZeneca HaltenDZ BANK
07.02.2025AstraZeneca HoldDeutsche Bank AG
06.02.2025AstraZeneca NeutralUBS AG
06.02.2025AstraZeneca HoldJefferies & Company Inc.
DatumRatingAnalyst
11:16AstraZeneca BuyGoldman Sachs Group Inc.
06.02.2025AstraZeneca OverweightJP Morgan Chase & Co.
03.02.2025AstraZeneca OverweightJP Morgan Chase & Co.
21.01.2025AstraZeneca BuyGoldman Sachs Group Inc.
15.01.2025AstraZeneca OverweightJP Morgan Chase & Co.
DatumRatingAnalyst
07.02.2025AstraZeneca HaltenDZ BANK
07.02.2025AstraZeneca HoldDeutsche Bank AG
06.02.2025AstraZeneca NeutralUBS AG
06.02.2025AstraZeneca HoldJefferies & Company Inc.
30.01.2025AstraZeneca NeutralUBS AG
DatumRatingAnalyst
12.11.2024AstraZeneca SellUBS AG
07.11.2024AstraZeneca SellUBS AG
05.11.2024AstraZeneca SellUBS AG
05.11.2024AstraZeneca SellDeutsche Bank AG
05.11.2024AstraZeneca SellUBS AG

Um die Übersicht zu verbessern, haben Sie die Möglichkeit, die Analysen für AstraZeneca PLC nach folgenden Kriterien zu filtern.

Alle: Alle Empfehlungen

Buy: Kaufempfehlungen wie z.B. "kaufen" oder "buy"
Hold: Halten-Empfehlungen wie z.B. "halten" oder "neutral"
Sell: Verkaufsempfehlungn wie z.B. "verkaufen" oder "reduce"